TFF3 Hypomethylation As a Novel Biomarker for Prostate Cancer

The present invention relates to a TFF3 gene as a marker of prostate cancer. The present invention thus relates to methods for diagnosing prostate cancer or predicting or prognosticating the disease outcome comprising steps of determining the methylation status of a TFF3 gene and/or the transcriptional and translational expression levels of a TFF3 gene. The present invention further relates to methods for monitoring disease progression in an individual having contracted prostate cancer as well as methods for determining the treatment regime of an individual having contracted prostate cancer comprising steps of determining the methylation status of a TFF3 gene and/or the transcriptional and translational expression levels of a TFF3 gene.

Patents:
WO 2,011,044,902   [MORE INFO]

Inventor(s): SOERENSEN KARINA DALSGAARD [DK]; VESTERGAARD ELSE MARIE [DK]; OERNTOFT TORBEN FALCK [DK]

Type of Offer: Sale



« More Biotech Patents

---